In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Previews (09/2008)

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Bone Building Start-Ups," features profiles of OsteoCorp, OsteoGeneX, Pradama, and Therosteon. Plus these Start-Ups Across Health Care: Aileron Therapeutics, Cohera Medical, CoLucid Pharmaceuticlas and Endogun Medical Systems.

You may also be interested in...



Pradama Inc.

University of Louisville spin-out Pradama is developing bone-targeting technology that it says will precisely deliver estrogen drugs to promote bone growth without the side effects of other estrogen receptor modulators. Preclinical tests on its lead product for osteoporosis will begin in the first quarter of 2009.

OsteoCorp Inc.

The class of drugs called beta-blockers--long used for heart disease and migraines--also prompts an increase in bone mass. OsteoCorp will repurpose beta blockers to build bone in the treatment of conditions like bone cancer and osteoporosis.

Therosteon BV

Rotterdam-based Therosteon is developing therapeutics for bone diseases including osteoporosis, osteoarthritis, and bone metastasis using its OsteoBLAST drug discovery platform, developed by company founder and chief scientific officer, Hans van Leeuwen.

Related Content

Related Companies

UsernamePublicRestriction

Register

PS142217

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel